

samples are established as LTP-TS and/or PDXs and little is known about the genetics and molecular properties of LTP-TS-forming GDCs and PDX. In this study, we aim to analyze the characteristics of LTP-TS-forming GDCs and PDXs. We tried primary sphere cultures from 56 glioma patient-derived samples and established 11 LTP-TS-GDCs out of 45 glioblastoma samples and no long-term sphere culture was isolated from grade 3 and grade 2 gliomas. LTP-TS-GDCs had self-renewal ability and possessed certain multipotency. However, they significantly less expressed SOX1, FOXG1 and TUBB3, whereas they expressed LGALS1 and EN1 significantly higher than normal neural stem/progenitor cells. In addition, we found that LTP-TS-GDCs shared the same genetic profiles with original patients' tumors. Furthermore, we investigated the genetic differences between the glioma tissues which were successfully established as LTP-TS-GDCs and those which were not. We found that glioma tissues with TERT promoter mutations and triple copy number alteration (CNA) [EGFR, CDKN2A, and PTEN loci] are significantly established as LTP-TS-GDCs. Lastly, we next investigated *in vivo* characteristics of glioma PDXs. We have injected glioma PDXs lines into immunodeficient mice brains and histopathologically analyzed the characteristics of xenografts. Each xenograft well recapitulated histological features of original patients' tumors and tumor cells remarkably invade through subventricular zone. In conclusion, each LTP-TS-GDCs and PDXs had various gene expression profiles, reflecting intratumoral and interpatient heterogeneities of glioma. In addition, TERT promoter mutations and triple CNA significantly correlated with success rate of LTP-TS-GDCs. These findings will be of use and advance the preclinical and translational researches of glioma.

**Key words:** glioma | long-term proliferating tumorsphere-forming glioma derived cells | patient derived xenografts

## TB-9

### AN ATTEMPT TO ESTABLISH A PATIENT-DERIVED BRAIN TUMOR CULTURE MODEL BY ORGANOID CULTURE METHOD

Hideki Kuroda<sup>1</sup>, Noriyuki Kijima<sup>1</sup>, Tomoyoshi Nakagawa<sup>1</sup>, Ryuichi Hirayama<sup>1</sup>, Yoshiko Okita<sup>1</sup>, Naoki Kagawa<sup>1</sup>, Haruhiko Kisima<sup>1</sup>; <sup>1</sup>Department of Neurosurgery, Osaka University, Osaka, Japan

**Background:** Molecular heterogeneity among and within tumors are one of the reasons for the poor survival rate of brain tumors even with the current standard therapy. However, monolayer culture and neuro-sphere culture (NS) use exogenous growth factors, so may not show the true nature of the tumor. And the culture establishment rate is low, especially low-grade tumors. Therefore, we used the glioblastoma organoid (GBO) culture method showed by Fadi to create culture models of various brain tumors and investigated their characteristics. **Methods:** We examined the establishment rate in pathological and genotypic types of 56 patients who underwent brain tumor resection at our hospital between January 2020 and June 2021 and were cultured with GBO or NS. If tumor cells are increased visually at 1 month after culture, we defined establishment. **Results:** There were 15 cases of glioblastoma, 7 cases of anaplastic astrocytoma, 7 cases of diffuse astrocytoma, 3 cases of diffuse midline glioma, 2 cases of anaplastic oligodendroglioma, 5 cases of oligodendroglioma, and 16 cases of others. The establishment rate was 76.5% by the GBO method and 40% by the NS method. By histological type, GBO: 80% in glioblastoma, NS: 58.3% in glioblastoma, GBO: 83.3% in AA, NS: 40% in AA, and GBO: 100% in DA. The IDH mutation and pTERT mutation were investigated in GBO: IDHwt/TERT+ 87.5%, IDHwt/TERT- 64.3%, IDHmt/TERT- 100%, and in NS: IDHwt/TERT+ 75%, IDHwt/TERT- 33.3%, IDHmt/TERT- 20% in NS. In addition, establishment was observed in GBO 2 case in medulloblastoma, 1 case in ependymoma. **Discussion and Conclusion:** This suggest that GBO can be used to establish culture models for low-grade tumors. In addition, GBO can establish culture earlier, so it is expected to be applicable to personalized therapies such as preclinical drug efficacy studies tailored to individual patients.

**Key words:** organoid | culture model | brain tumor

## IMMUNOLOGY (IM)

### IM-2

#### POSSIBILITY OF IMMUNOTHERAPY FOR THE GLIOBLASTOMA PATIENTS WITH O6-METHYL-GUANINE DNA METHYLTRANSFERASE (MGMT) EXPRESSION OR PROMOTER UNMETHYLATED

Yoshihiro Kushihara<sup>1</sup>, Shota Tanaka<sup>1</sup>, Shohei Nanbu<sup>1</sup>, Kazuha Kugasawa<sup>1</sup>, Erika Yamasawa<sup>1</sup>, Hirokazu Takami<sup>1</sup>, Shunsaku Takayanagi<sup>1</sup>, Kazuhiro Kakimi<sup>2</sup>, Nobuhito Saito<sup>1</sup>; <sup>1</sup>Department of Neurosurgery, The University of Tokyo <sup>2</sup>Department of Immunotherapeutics, The University of Tokyo Hospital

**Background:** MGMT is a DNA repair protein that removes the cytotoxic O6-methylguanine (O6MG) DNA lesions generated by TMZ;

thereby, MGMT expression is mechanistically linked to TMZ resistance. However, thus far, there is no effective treatment for these patients with MGMT promoter unmethylated. Therefore, a new treatment for GBM patients with MGMT expression is urgently needed. To this end, we examined the tumor microenvironment in GBM with or without MGMT expression. **Methods:** Based on The Cancer Genome Atlas (TCGA) primary GBM cohort, the tumor-infiltrating lymphocytes (TILs) expression level was calculated using the CIBERSORTx algorithms and the single-sample Gene Set Enrichment Analysis (ssGSEA) method. Furthermore, the differential expression gene analysis was conducted and pathway analysis was performed using Ingenuity Pathway Analysis (IPA). The results were validated using the GBM cohort from the Chinese Glioma Genome Atlas (CGGA) database. In addition, TILs were isolated from 13 surgically removed primary GBM tumors in our institution. Their responses to autologous tumors were evaluated by IFN $\gamma$  ELISA. **Results:** T cells CD8 score by CIBERSORTx was significantly higher in the MGMT-high tumor. Similarly, ssGSEA scores for activated CD8 T cell, Macrophage, activated B cell, and Type 1 T helper cell were significantly higher in the MGMT-high tumor. Conversely, T cells CD4 naive was significantly higher in the MGMT-low tumor. Consistently, tumor-reactive TILs were detected in the MGMT-high tumor. Pathway analysis showed that Rictor was highly enriched in the MGMT-high tumor and Rictor inhibited lymphocyte activation. **Conclusion:** In this study, we demonstrated that macrophage was highly activated in the MGMT-high tumors. Thus, CSF-1R inhibitor can be combined with immunotherapy in these MGMT-high tumors to enhance anti-tumor immune responses. In addition, TMZ + mTOR2 inhibitors + PD-1 inhibitors may be effective against the MGMT-L group.

**Key words:** MGMT | CD8+T cell | tumor microenvironment

### IM-4

#### IMPACT OF OHSV ACTIVATED NOTCH SIGNALING IN TUMOR MICROENVIRONMENT AND ITS IMPACT ON ANTI-TUMOR IMMUNITY

Otani Yoshihiro<sup>1,2</sup>, Ji Young Yoo<sup>3</sup>, Sean E Lawler<sup>3</sup>, Antonio E Chiocca<sup>3</sup>, Balveen Kaur<sup>2</sup>; <sup>1</sup>Department of Neurological Surgery, Okayama University Hospital, Okayama, Japan <sup>2</sup>Department of Neurosurgery, University of Texas Health Science Center at Houston <sup>3</sup>Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School and Brigham and Women's Hospital

Oncolytic herpes simplex virus-1 (oHSV) is novel FDA-approved immunotherapy for advanced melanoma patients in US. Also, oHSV is recently approved for the treatment of recurrent GBM in Japan. We have shown that oHSV treatment of GBM cells induces NICD cleavage and NOTCH activation in adjacent uninfected glioma cells via HSV-1 microRNA-H16 (Otani Y and Yoo JY, Clin Cancer Res, 2020), however, the consequences of NOTCH on immunotherapy in GBM is unknown. Here we have investigated the impact of oHSV-induced NOTCH signaling on the tumor microenvironment (TME). Analysis of TCGA GBM data and experimental murine models revealed NOTCH induced immunosuppressive myeloid cell recruitment and limited anti-tumor immunity. In oHSV treated tissue, viral infection educated tumor associated macrophages to secrete CCL2 which recruited monocytic myeloid derived suppressor cell (MDSC) that attenuated anti-tumor immunity. Consistent with this, CCL2 induction was also observed in serum of recurrent GBM patients treated with oHSV (NCT03152318). Importantly, blockade of NOTCH signaling reduced the oHSV induced immunosuppressive environment and activated a CD8 dependent anti-tumor memory response. These findings present the opportunities for combination therapies that can help improve therapeutic benefit and anti-tumor immunity in GBM.

**Key words:** Immunotherapy | Oncolytic HSV | Tumor microenvironment

### IM-6

#### HVJ-E CONTAINING PD-L1 SIRNA INHIBITS IMMUNOSUPPRESSIVE ACTIVITIES AND ELICITS ANTITUMOR IMMUNE RESPONSES IN GLIOMA

Narushi Sugii<sup>1,2</sup>, Masahide Matsuda<sup>1</sup>, Genki Okumura<sup>3</sup>, Akira Shibuya<sup>3</sup>, Eiichi Ishikawa<sup>1</sup>; <sup>1</sup>Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan <sup>2</sup>Department of Neurosurgery, University of Tsukuba Hospital, Ibaraki, Japan <sup>3</sup>Immunology Lab, University of Tsukuba, Ibaraki, Japan

Inactivated Sendai virus particle, hemagglutinating virus of Japan-envelope (HVJ-E), is a non-replicating virus-derived vector, in which the genomic RNA of Sendai virus (HVJ) has been destroyed. HVJ-E is a promising vector that enables the highly efficient and safe introduction of enclosed molecules such as RNA into target cells. Moreover, HVJ-E provokes robust antitumoral immunity by activating natural killer (NK) cells and CD8+ T lymphocytes and their induction into the tumor periphery, and by suppressing regulatory T lymphocytes (Treg) locally in the tumor. In the present study, we investigated a novel combination of antitumor immunotherapy